OncoMatch/Colorectal Cancer (CRC)/BRAF
Colorectal Cancer (CRC)BRAF Clinical Trials
BRAF V600E mutations occur in 10–15% of metastatic CRC and are associated with poor prognosis, right-sided tumors, and frequent MSI-H co-occurrence. The encorafenib plus cetuximab combination (with or without binimetinib) is FDA-approved for BRAF V600E-mutant metastatic CRC. Trials investigate triplet combinations with immunotherapy, novel BRAF inhibitors, and strategies for non-V600E BRAF alterations.
Top recruiting BRAF Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 29 trials matched to your profile →
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Alliance for Clinical Trials in Oncology
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Assistance Publique - Hôpitaux de Paris
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Merck Sharp & Dohme LLC
Browse other molecular targets with active Colorectal Cancer (CRC) trials.